Bladder Urothelial Carcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | FGFR3 p.R248C | Bladder Urothelial Carcinoma | Erdafitinib | FDA |
| Sensitivity (+) | FGFR3 p.S249C | Bladder Urothelial Carcinoma | Erdafitinib | FDA |
| Sensitivity (+) | FGFR3 p.G370C | Bladder Urothelial Carcinoma | Erdafitinib | FDA |
| Sensitivity (+) | FGFR3 p.Y373C | Bladder Urothelial Carcinoma | Erdafitinib | FDA |
| Sensitivity (+) | FGFR3::TACC3 | Bladder Urothelial Carcinoma | Erdafitinib | FDA |
| Sensitivity (+) | FGFR3 p.R248C | Bladder Urothelial Carcinoma | Erdafitinib | HC |
| Sensitivity (+) | FGFR3 p.S249C | Bladder Urothelial Carcinoma | Erdafitinib | HC |
| Sensitivity (+) | FGFR3 p.G370C | Bladder Urothelial Carcinoma | Erdafitinib | HC |
| Sensitivity (+) | FGFR3 p.Y373C | Bladder Urothelial Carcinoma | Erdafitinib | HC |
| Sensitivity (+) | FGFR3::TACC3 | Bladder Urothelial Carcinoma | Erdafitinib | HC |